EICHORCondition: Platinum-resistant Ovarian Cancer · Sponsor: InxMed (Shanghai) Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).
This description comes directly from the study's public registry record.
Jack Zhang · 86-18611511983 · jack.zhang@inxmed.com
Bohong Zhang · 86-18801955197 · bohong.zhang@inxmed.com
Always discuss trial participation with your own doctor first.
| Anyang Cancer Hospital | Anyang, China | Recruiting |
| Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College | Beijing, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Affiliated Obstetrics and Gynecology Hospital of Zhejiang University | Hangzhou, China | Recruiting |
| Tianjin Cancer Hospital | Tianjin, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05551507